Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study

Secukinumab, a fully human monoclonal antibody neutralizing interleukin‐17A, has been shown to have significant efficacy in the treatment of moderate to severe psoriasis. Long‐term (3‐year) efficacy and safety of secukinumab in Japanese patients with moderate to severe psoriasis were evaluated in an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Dermatol
Hauptverfasser: Okubo, Yukari, Ohtsuki, Mamitaro, Morita, Akimichi, Yamaguchi, Masako, Shima, Tomohiro, Tani, Yumiko, Nakagawa, Hidemi
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590222/
https://ncbi.nlm.nih.gov/pubmed/30672623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.14761
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge